Background The increasing use of biologics is accompanied by a risk of hepatitis B (HBV)
and C virus (HCV) reactivation. Objective To determine the predictors of HBV and HCV …

Background Patients with psoriasis on biologic therapies and a history of viral hepatitis carry
a risk for reactivation. Objective We evaluated safety of biologic therapies in psoriasis …

Introduction and objectives A 5% risk of reactivation of hepatitis B virus (HBV) infection has
been reported in patients with diseases other than psoriasis treated with tumor necrosis …

Considered more efficacious and safer than traditional systemic drugs, biologic therapies
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …

Introduction: Biologics are highly effective, important treatment options for moderate-to-
severe psoriasis. Biologics are well tolerated and have few side effects. However, the use of …

The use of anti‐tumor necrosis factor (TNF)‐α therapy in patients with psoriasis who are
hepatitis B virus (HBV) carriers is usually not recommended, and routine antiviral …

Introduction Notwithstanding their numerous advantages, biological treatments have many
limitations when treating patients with psoriasis (PsO) and hepatitis B (HB). Clinicians need …

The risk of hepatitis B virus (HBV) reactivation (HBVr) in chronic HBV carriers, in occult HBV
patients or in acute HBV patients affected by psoriasis and treated with anti-tumor necrosis …

Background Tumor necrosis factor inhibitory agents are currently considered to be
contraindicated in psoriatic patients with hepatitis B. Objective We aim to provide guidance …

Some biological therapies for psoriasis can cause the reactivation of viral infections.
Although recent studies suggest no increased rate of reactivation with biological therapies …